期刊文献+

高效液相色谱法测定米拉贝隆中对映异构体 被引量:1

Determination of enantiomer in mirabegron by HPLC
原文传递
导出
摘要 目的 建立手性高效液相色谱方法测定米拉贝隆中的对映异构体。方法 采用对照品法进行定性定量分析,使用Daicel Chiralpak AY-H(4.6 mm×250 mm,5 μm)色谱柱,流动相为正己烷-乙醇-二乙胺(650∶350∶1),流速为1.0 mL·min^(-1),检测波长为240 nm,柱温为35℃,进样体积为10 μL。结果 米拉贝隆与其对映异构体能有效分离,分离度大于1.5;米拉贝隆在0.461~5.975 μg·mL^(-1)与峰面积线性关系良好(r=0.9998);低、中、高质量浓度平均加样回收率分别为89.5%、94.8% 和92.8%,RSD分别为2.9%、2.9%和1.6%(n=3);供试品溶液在室温条件下24 h内基本稳定。经检测,6批米拉贝隆中均未检出对映异构体。结论 本方法经方法学验证,可用于米拉贝隆中对映异构体的测定。 Objective To develop an HPLC method to determine enantiomer in mirabegron.Methods Reference substance was used for the qualitative and quantitative determination.The separation was performed on a Daicel Chiralpak AY-H column (4.6 mm×250 mm,5 μm) with the mobile phase of hexane-ethanol-diethylamine (650∶350∶1) at 1.0 mL·min^(-1),the detective wavelength was 240 nm,the column temperature was 35℃and the injection volume was 10 μL.Results Mirabegron and enantiomer were effectively separated under the above conditions with the resolution higher than 1.5.The calibration curves were linear at 0.461~5.975 μg·mL^(-1)(r=0.9998).The recoveries were 89.5%,94.8%,and 92.8% at low,medium and high concentrations with the RSD of 2.9%,2.9% and 1.6%,respectively (n=3).The test solution was basically stable within 24 h at room temperature.No enantiomers were detected in the 6 batches of mirabegron.Conclusion The method is suitable for the determination of enantiomer in mirabegron by methodology validation.
作者 陈秋 樊梦妮 李国柱 兰公剑 CHEN Qiu;FAN Meng-ni;LI Guo-zhu;LAN Gong-jian(Nanjing Chia Tai Tianqing Pharmaceutical Co.,Ltd,Nanjing 210046)
出处 《中南药学》 CAS 2022年第11期2631-2634,共4页 Central South Pharmacy
关键词 米拉贝隆 对映异构体 手性药物检测 高效液相色谱法 mirabegron enantiomer chiral drug detection high performance liquid chromatography
  • 相关文献

参考文献5

二级参考文献72

  • 1US Food and Drug Administration. FDA approves Myrbetriq for overactive bladder[EB/OL].[2012-6-28]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310096.html.
  • 2MARUYAMA T, SUZUKI T, ONDA K, et al. Amide derivatives or salts thereof: US, 6346532B1[P].2002-02-12.
  • 3TAKASU T, UKAI M, SATO S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function[J]. J Pharmacol Exp Ther, 2007, 321(2): 642-647.
  • 4TAKUSAGAWA S, VAN L, JAN J, et al. Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers[J]. Drug Metab Dispos, 2012, 40(4): 815-824.
  • 5IRWIN DE, MILSOM I, HUNSKAAR S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study[J]. Eur Urol, 2006,50(6):1306 -1315.
  • 6COYNE KS, SEXTON CC, THOMPSON CL, et al. The preva- lence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS ( Epi- LUTS) study [ J ]. BJU lnt, 2009,104 (3) :352 - 360.
  • 7IRWIN D E, KOPP ZS, AGATEP B, et al. Worldwide preva- lence estimates of lower urinary tract symptoms, overactive blad- der, urinary incontinence and bladder outlet obstruction [ J ]. BJU Int, 2011,108(7) :1132 - 1138.
  • 8LEE RT, BAMBERGER M, ELLSWORTH P. Impact of mirabe- gron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency[ Jl. Res Rep Urol, 2013,5 (4) :147 - 157.
  • 9ANDERSSON K. New developments in the management of over- active bladder: focus on mirabegron and onabotulinumtoxinA [ J ]. Ther Clin Risk Manage, 2013,9 ( 1 ) : 161 - 170.
  • 10OTSUKA A, SHINBO H, MATSUMOTO R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium [ J]. Naunyn Schmiedebergs Arch Pharmacol, 2008,377(4-6) :473 -481.

共引文献29

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部